Business Context and Reporting Period
This Form 8-K is a current report filed by Neoleukin Therapeutics, Inc. (trading symbol: NLTX) on November 17, 2021. The company is incorporated in Delaware and its principal executive offices are located in Seattle, Washington. The report addresses a specific corporate governance event rather than periodic financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding personnel changes and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the departure of a key executive officer:
- Resignation: Holly Vance has resigned from her positions as General Counsel and Corporate Secretary.
- Effective Date: The resignation notice was received on November 17, 2021.
- Reason: Ms. Vance is resigning to pursue another opportunity.
- Transition Plan: The Company and Ms. Vance are determining the transition period. She is expected to provide consulting services on an as-needed basis during this time.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks related to the resignation. The document focuses solely on the factual notification of the officer's departure and the intent to maintain consulting support during the transition.
Investor Verification Checklist
- Confirm the exact end date of Holly Vance's employment and the duration of her consulting arrangement.
- Verify if the Company has appointed an interim General Counsel or Corporate Secretary to replace Ms. Vance.
- Review subsequent filings to ensure no other key personnel departures occurred concurrently.
- Check the Company's latest 10-K or 10-Q for the most recent financial position, as this 8-K contains no financial data.